These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

258 related items for PubMed ID: 23392467

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Atazanavir pharmacokinetics with and without tenofovir during pregnancy.
    Mirochnick M, Best BM, Stek AM, Capparelli EV, Hu C, Burchett SK, Rossi SS, Hawkins E, Basar M, Smith E, Read JS, IMPAACT 1026s Study Team.
    J Acquir Immune Defic Syndr; 2011 Apr 15; 56(5):412-9. PubMed ID: 21283017
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection.
    Kiser JJ, Fletcher CV, Flynn PM, Cunningham CK, Wilson CM, Kapogiannis BG, Major-Wilson H, Viani RM, Liu NX, Muenz LR, Harris DR, Havens PL, Adolescent Trials Network for HIV/AIDS Interventions.
    Antimicrob Agents Chemother; 2008 Feb 15; 52(2):631-7. PubMed ID: 18025112
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Pharmacokinetics of tenofovir during pregnancy and postpartum.
    Best BM, Burchett S, Li H, Stek A, Hu C, Wang J, Hawkins E, Byroads M, Watts DH, Smith E, Fletcher CV, Capparelli EV, Mirochnick M, International Maternal Pediatric and Adolescent AIDS Clinical Trials (IMPAACT) P1026s Team.
    HIV Med; 2015 Sep 15; 16(8):502-11. PubMed ID: 25959631
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Safety and exposure of once-daily ritonavir-boosted atazanavir in HIV-infected pregnant women.
    Conradie F, Zorrilla C, Josipovic D, Botes M, Osiyemi O, Vandeloise E, Eley T, Child M, Bertz R, Hu W, Wirtz V, McGrath D.
    HIV Med; 2011 Oct 15; 12(9):570-9. PubMed ID: 21569187
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Steady-state pharmacokinetics of tenofovir-based regimens in HIV-infected pediatric patients.
    King JR, Yogev R, Jean-Philippe P, Graham B, Wiznia A, Britto P, Carey V, Hazra R, Acosta EP, P1058 Protocol Team.
    Antimicrob Agents Chemother; 2011 Sep 15; 55(9):4290-4. PubMed ID: 21670182
    [Abstract] [Full Text] [Related]

  • 14. Pharmacokinetics of atazanavir/ritonavir among HIV-infected Thai children concomitantly taking tenofovir disoproxil fumarate.
    Bunupuradah T, Techasaensiri C, Keadpudsa S, Thammajaruk N, Srimuan A, Sahakijpicharn T, Prasitsuebsai W, Ananworanich J, Puthanakit T, HIV-NAT 146 Study Team.
    Pediatr Infect Dis J; 2014 Dec 15; 33(12):e316-9. PubMed ID: 24983717
    [Abstract] [Full Text] [Related]

  • 15. Tenofovir coadministration is not associated with lower unboosted atazanavir plasma exposure in the clinical setting.
    Calcagno A, Bonora S, Tettoni MC, D'Avolio A, Perri GD, Lanzafame M, Penco G.
    J Acquir Immune Defic Syndr; 2009 Nov 01; 52(3):431-2. PubMed ID: 19858926
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir pharmacokinetics in HIV-infected patients.
    Dailly E, Tribut O, Tattevin P, Arvieux C, Perré P, Raffi F, Jolliet P.
    Eur J Clin Pharmacol; 2006 Jul 01; 62(7):523-6. PubMed ID: 16763827
    [Abstract] [Full Text] [Related]

  • 18. Pilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir-ritonavir.
    Pruvost A, Negredo E, Théodoro F, Puig J, Levi M, Ayen R, Grassi J, Clotet B.
    Antimicrob Agents Chemother; 2009 May 01; 53(5):1937-43. PubMed ID: 19273671
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Population pharmacokinetics of atazanavir/ritonavir in HIV-1-infected children and adolescents.
    Foissac F, Blanche S, Dollfus C, Hirt D, Firtion G, Laurent C, Treluyer JM, Urien S.
    Br J Clin Pharmacol; 2011 Dec 01; 72(6):940-7. PubMed ID: 21649692
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.